The abstract is read at the publisher; the summary is JClub's.
SSH1 knockdown in tauopathy models lowers steady-state MAPT/tau levels by enhancing autophagic flux, driven by ATG9A recruitment to the ER-PAS and early autophagosome formation.
- Why it matters: MAPT/tau accumulation in Alzheimer disease and related tauopathies demands druggable regulators of tau clearance, but the control points governing autophagy-dependent degradation remain incomplete.
- What they did: A Drosophila genetic screen for modifiers of MAPT/tau-induced behavioral deficits identified SSH1 as a consistent reducer of MAPT/tau, then human tauopathy cell models assessed autophagic flux, ATG9A trafficking, and autophagosome biogenesis.
- The result: SSH1 depletion mobilizes ATG9A to the ER-PAS and accelerates vesicle biogenesis, and the MAPT/tau-lowering effect in flies is abolished by Dm Atg9 haploinsufficiency; in vitro, recombinant SSH1 reduces ATG9A phosphorylation with actin.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.